Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Haisco Pharmaceutical enters into a licensing agreement with Sentivera, securing $75.89 million in upfront and equity consideration. This collaboration enhances Haisco's strategy for international innovation in drug development.
PRIVATEAug 25, 2026•about 3 hours ago
Amount Raised
$75.9 Million
Round Type
Venture - Series Unknown
ChinaBiotechnologyHealth CarePharmaceutical
Investors
Arch Venture PartnersPopulation Health Partners
Description
Haisco Pharmaceutical Group announced an exclusive licensing agreement with Sentivera, granting rights to develop a preclinical innovative drug. The total deal is valued at over $1.5 billion, including $75.89 million upfront. This partnership aims to boost Haisco's international strategy and generate long-term investment returns. It underscores strong market confidence in the project, contributing to the internationalization of innovative drugs from China.
Company Information
Company
Haisco Pharmaceutical Group Ltd
Location
China
About
Haisco Pharmaceutical Group Co., Ltd. is a benchmark enterprise in China's innovative drug sector, focusing on innovation-driven growth and global expansion. The company has a diversified R&D pipeline with more than 70 programs across therapeutic areas such as immunology, oncology, and metabolic disorders. Haisco is committed to advancing its R&D efforts, with substantial investments aimed at developing original medicines to address unmet clinical needs globally.
Don't miss Haisco Pharmaceutical Group Ltd's next move
Get an email the moment Haisco Pharmaceutical Group Ltd raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Haisco Pharmaceutical Group Ltd's next move
ChinaBiotechnologyHealth CarePharmaceutical